Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.

Miriam Saiz-RodriguezDolores OchoaCarmen BelmonteManuel RománDanilo Vieira de LaraPablo ZubiaurDora KollerGina MejíaFrancisco Abad-Santos

Published in: Journal of psychopharmacology (Oxford, England) (2019)

CYP1A2 polymorphisms affect agomelatine pharmacokinetics. CYP1A2 phenotype inferred from the genotyping of CYP1A2*1C, *1F and *1B alleles might be a potential predictor of agomelatine exposure. ABCB1 G2677T/A could affect agomelatine absorption, as subjects with A/A+A/T genotypes had lower agomelatine concentration and they take more time to reach the maximum concentration.

Keyphrases

genome wide
gene expression
climate change
single cell